Phase III Data for Gilead Sciences’ Darusentan Accepted as Late-Breaker Presentation at ASH 2009

http://www.therapeuticsdaily.com/news/article.cfm?contentvalue=618210&contenttype=newsarchive&channelID=30

Comments are closed.